173 related articles for article (PubMed ID: 11888344)
1. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
Giacobini E
Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH
Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237
[TBL] [Abstract][Full Text] [Related]
3. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.
Nordberg A; Ballard C; Bullock R; Darreh-Shori T; Somogyi M
Prim Care Companion CNS Disord; 2013; 15(2):. PubMed ID: 23930233
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and molecular docking studies of 5-trifluoromethoxy-2-indolinones as cholinesterase dual inhibitors.
Soylu-Eter Ö; Özsoy N; Karalı N
Future Med Chem; 2024 Apr; 16(7):623-645. PubMed ID: 38470247
[No Abstract] [Full Text] [Related]
5. Cholinesterases and the fine line between poison and remedy.
Pope CN; Brimijoin S
Biochem Pharmacol; 2018 Jul; 153():205-216. PubMed ID: 29409903
[TBL] [Abstract][Full Text] [Related]
6. Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.
Ferris S; Nordberg A; Soininen H; Darreh-Shori T; Lane R
Pharmacogenet Genomics; 2009 Aug; 19(8):635-46. PubMed ID: 19617863
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of 9-Aminoacridine Derivatives as Anti-Alzheimer Agents.
Munawar R; Mushtaq N; Arif S; Ahmed A; Akhtar S; Ansari S; Meer S; Saify ZS; Arif M
Am J Alzheimers Dis Other Demen; 2016 May; 31(3):263-9. PubMed ID: 26385945
[TBL] [Abstract][Full Text] [Related]
8. aChE and BuChE inhibition by rivastigmin have no effect on peripheral insulin resistance in elderly patients with Alzheimer disease.
Isik AT; Bozoglu E; Eker D
J Nutr Health Aging; 2012 Feb; 16(2):139-41. PubMed ID: 22323348
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterases are down-expressed in human colorectal carcinoma.
Montenegro MF; Ruiz-Espejo F; Campoy FJ; Muñoz-Delgado E; de la Cadena MP; Rodríguez-Berrocal FJ; Vidal CJ
Cell Mol Life Sci; 2006 Sep; 63(18):2175-82. PubMed ID: 16909200
[TBL] [Abstract][Full Text] [Related]
10. Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.
Annicchiarico R; Federici A; Pettenati C; Caltagirone C
Ther Clin Risk Manag; 2007 Dec; 3(6):1113-23. PubMed ID: 18516265
[TBL] [Abstract][Full Text] [Related]
11. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
12. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
13. Active site gating and substrate specificity of butyrylcholinesterase and acetylcholinesterase: insights from molecular dynamics simulations.
Fang L; Pan Y; Muzyka JL; Zhan CG
J Phys Chem B; 2011 Jul; 115(27):8797-805. PubMed ID: 21682268
[TBL] [Abstract][Full Text] [Related]
14. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of AChE by malathion and some structurally similar compounds.
Krstić DZ; Colović M; Kralj MB; Franko M; Krinulović K; Trebse P; Vasić V
J Enzyme Inhib Med Chem; 2008 Aug; 23(4):562-73. PubMed ID: 18608787
[TBL] [Abstract][Full Text] [Related]
16. Comparison of active sites of butyrylcholinesterase and acetylcholinesterase based on inhibition by geometric isomers of benzene-di-N-substituted carbamates.
Chiou SY; Huang CF; Hwang MT; Lin G
J Biochem Mol Toxicol; 2009; 23(5):303-8. PubMed ID: 19827033
[TBL] [Abstract][Full Text] [Related]
17. Studying enzyme binding specificity in acetylcholinesterase using a combined molecular dynamics and multiple docking approach.
Kua J; Zhang Y; McCammon JA
J Am Chem Soc; 2002 Jul; 124(28):8260-7. PubMed ID: 12105904
[TBL] [Abstract][Full Text] [Related]
18. Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis.
Harel M; Sussman JL; Krejci E; Bon S; Chanal P; Massoulié J; Silman I
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10827-31. PubMed ID: 1438284
[TBL] [Abstract][Full Text] [Related]
19. Cholinesterases: new roles in brain function and in Alzheimer's disease.
Giacobini E
Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
[TBL] [Abstract][Full Text] [Related]
20. History and new developments of assays for cholinesterase activity and inhibition.
Miao Y; He N; Zhu JJ
Chem Rev; 2010 Sep; 110(9):5216-34. PubMed ID: 20593857
[No Abstract] [Full Text] [Related]
[Next] [New Search]
